Ibrance (palbociclib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Ibrance (palbociclib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Ibrance (palbociclib) is a targeted therapy known as a CDK4/6 inhibitor used primarily for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, often in combination with hormonal therapies. Phesgo, on the other hand, is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with hyaluronidase, and is indicated for the treatment of HER2-positive breast cancer in early and metastatic stages, administered subcutaneously to enhance absorption. The choice between Ibrance and Phesgo would depend on the specific subtype of breast cancer a patient has, as Ibrance is not suitable for HER2-positive cancers, whereas Phesgo is specifically designed for them, thus a thorough discussion with an oncologist is essential to determine the appropriate treatment based on the cancer's hormonal receptor and HER2 status.
Difference between Ibrance and Phesgo
| Metric | Ibrance (palbociclib) | Phesgo (pertuzumab, trastuzumab, and hyaluronidase) |
|---|---|---|
| Generic name | Palbociclib | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf |
| Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | HER2-positive breast cancer |
| Mechanism of action | CDK4/6 inhibitor | HER2 inhibitors, enzyme |
| Brand names | Ibrance | Phesgo |
| Administrative route | Oral | Subcutaneous injection |
| Side effects | Neutropenia, leukopenia, infections, fatigue | Diarrhea, alopecia, nausea, fatigue, neuropathy |
| Contraindications | Hepatic impairment, existing neutropenia | None known |
| Drug class | Antineoplastic agents, kinase inhibitors | Antineoplastic agents, monoclonal antibodies |
| Manufacturer | Pfizer | Genentech (Roche) |
Efficacy
Ibrance (Palbociclib) Efficacy in Breast Cancer
Ibrance (palbociclib) is a targeted therapy drug that is used to treat certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Ibrance works by inhibiting cyclin-dependent kinases (CDK) 4 and 6, which are proteins that regulate cell division. By blocking these proteins, Ibrance helps to stop cancer cells from growing and dividing.
Clinical trials have demonstrated the efficacy of Ibrance in improving progression-free survival in patients with advanced breast cancer. When used in combination with letrozole or fulvestrant, two types of hormone therapy, Ibrance has been shown to significantly delay the progression of breast cancer compared to hormone therapy alone. This benefit has been observed in both premenopausal and postmenopausal women with HR+/HER2- advanced breast cancer.
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) Efficacy in Breast Cancer
Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, and is used for the treatment of HER2-positive breast cancer. Pertuzumab and trastuzumab work together to target the HER2 protein, which is overexpressed in some breast cancer cells, leading to the growth and spread of cancer. By blocking HER2, these drugs can slow down or stop the progression of the disease. Hyaluronidase is included to increase the absorption of the drugs.
The efficacy of Phesgo has been established through clinical trials where it is administered in combination with chemotherapy. It has been shown to improve overall survival and progression-free survival in patients with HER2-positive early breast cancer, metastatic breast cancer, or locally recurrent, unresectable breast cancer. Phesgo offers the convenience of subcutaneous administration, which can be less time-consuming and more comfortable for patients compared to intravenous administration of the individual components.
Regulatory Agency Approvals
Ibrance
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Phesgo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Ibrance or Phesgo today
If Ibrance or Phesgo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us